Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743106 | 0.90 | PRMT5 (0.31) | PRMT5WDR77 | |
| SCHEMBL23120206 | 0.87 | PRMT5 (0.35) | PRMT5WDR77METTL3NNMT | |
| SCHEMBL15381065 | 0.83 | NNMT (0.35) | NNMT | |
| SCHEMBL17302255 | 0.83 | PRMT5 (0.41) | PRMT5WDR77METTL3 | |
| SCHEMBL17302256 | 0.83 | PRMT5 (0.30) | PRMT5WDR77 | |
| SCHEMBL23120133 | 0.82 | PRMT5 (0.42) | PRMT5WDR77METTL3 | |
| SCHEMBL30941081 | 0.82 | PRMT5 (0.42) | PRMT5WDR77METTL3 | |
| SCHEMBL23120331 | 0.81 | ACACB (0.33) | PRMT5WDR77 | |
| SCHEMBL17302276 | 0.80 | PRMT5 (0.34) | PRMT5WDR77 | |
| SCHEMBL17936459 | 0.80 | PRMT5 (0.34) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384519-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2022-06-16 | — | — | US | disclosed |
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | PRMT5 84/4885WDR77 111/4885JAK2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.